Dare Bioscience, Inc. quarterly report, Q3 FY2014

Filing summary

Issuer discrepancy: The supplied 10-Q is for Cerulean Pharma Inc., not Dare Bioscience, Inc. It covers the quarter ended September 30, 2014 and was signed November 13, 2014. Confirm that this is the intended filing before relying on the figures.

Business context

Cerulean was a clinical-stage oncology company developing nanoparticle-drug conjugates. It reported no product sales and said commercialization, if achieved, was several years away. Its lead program, CRLX101, was being studied in cancer trials; CRLX301 remained in preclinical development.

Financial results and liquidity

MetricQ3 2014Q3 2013Nine months 2014Nine months 2013
Revenue$0$0$80,000$0
Research and development$2.928 million$1.586 million$7.071 million$8.260 million
General and administrative$2.441 million$1.227 million$5.980 million$4.591 million
Net loss$5.558 million$3.198 million$15.875 million$13.663 million
Net loss per share$0.28$4.40$1.26$20.96

Revenue was immaterial and generated no meaningful operating margin; the company remained loss-making. Q3 operating expenses rose 91% to $5.369 million, primarily reflecting higher clinical-development and public-company costs. Nine-month operating expenses were nearly flat at $13.051 million, as lower R&D partly offset higher G&A. Nine-month net loss increased 16%, including a $2.493 million noncash loss on conversion of debt at the IPO.

  • Cash and liquidity: Cash and cash equivalents were $57.786 million at September 30, 2014, versus $5.488 million at December 31, 2013. Management estimated available cash would fund operations, debt service, and capital expenditures into the first quarter of 2016, subject to assumptions and execution.
  • Cash flow: Nine-month operating cash use was $13.453 million, compared with $13.343 million in 2013; investing cash use was $76,000. Financing provided $65.827 million, including $59.861 million in net IPO proceeds.
  • Debt: $4.2 million of principal remained outstanding under the Lighthouse loan agreement, bearing 8.25% interest and secured by substantially all assets other than intellectual property. The balance sheet classified $3.347 million as current and $587,000 as long-term.
  • Equity and financing: The April 2014 IPO and over-allotment raised approximately $59.9 million net. Preferred shares and convertible notes converted into common stock at the IPO; common shares outstanding were 20,124,764 at September 30.

Changes, outlook, and significant items

  • CRLX101 R&D rose 106% in Q3 year over year, mainly due to the randomized Phase 2 renal-cell-carcinoma trial and investigator-sponsored studies. The company disclosed that enrollment at RCC trial sites was below plan and that it intended to add sites.
  • Management planned to initiate a CRLX301 Phase 1 trial by year-end 2014 and indicated a $250,000 development milestone would be payable upon initiation. It anticipated higher R&D and public-company costs and said additional capital would be needed to complete development and commercialization plans.
  • Potential 2015 randomized Phase 2 CRLX101 trials in ovarian and neoadjuvant rectal cancer depended on positive investigator-sponsored trial results. Management said those programs would require additional financing if pursued.
  • The company disclosed that CRLX101 had previously failed to meet the primary overall-survival endpoint in a Phase 2 non-small-cell lung cancer trial. It cautioned that preliminary investigator-sponsored results were not final and might not be confirmed in company-sponsored trials.
  • After quarter-end, CEO Oliver Fetzer resigned effective October 29, 2014. Board member Paul Friedman became executive chairman, and COO Christopher Guiffre became principal executive officer pending recruitment of a new CEO. The filing said the resignation involved no disagreement.
  • Other disclosed exposures included clinical-trial enrollment and outcome uncertainty, regulatory and manufacturing risks, reliance on third-party suppliers and investigators, intellectual-property/license risks, and possible need for further equity or debt financing. A lease amendment added approximately 8,628 square feet through February 2016, with $514,000 of base rent.

Most important facts to verify

  1. Verify that the Cerulean Pharma filing—not a Dare Bioscience filing—is the intended source.
  2. Check the reported $57.8 million cash balance, $13.5 million nine-month operating cash use, and management’s first-quarter 2016 runway estimate against subsequent filings and actual spending.
  3. Track RCC trial enrollment and results, and confirm whether the planned CRLX301 Phase 1 trial began on schedule.
  4. Review the Lighthouse loan’s repayment schedule, collateral and covenants, and the company’s subsequent financing needs.
  5. Assess the impact of the CEO transition and whether later leadership, clinical, or regulatory developments changed the stated plans.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.